Search Results
You are looking at 1 - 1 of 1 items for
- Author: J Wrin x
- Refine by access: Content accessible to me x
Search for other papers by O Gajanandana in
Google Scholar
PubMed
Search for other papers by K Irvine in
Google Scholar
PubMed
Search for other papers by PA Grant in
Google Scholar
PubMed
Search for other papers by GL Francis in
Google Scholar
PubMed
Search for other papers by SE Knowles in
Google Scholar
PubMed
Search for other papers by J Wrin in
Google Scholar
PubMed
Search for other papers by JC Wallace in
Google Scholar
PubMed
Search for other papers by PC Owens in
Google Scholar
PubMed
Long-Arg3-IGF-I (LR3IGF-I) is a synthetic analog of IGF-I that has much lower affinity for IGF-binding proteins than do native IGFs-I and -II. Comparisons of the effects of LR3IGF-I with those of IGFs-I and-II in in vitro and in vivo studies have proved useful in defining the functions of IGF-binding proteins. We have developed a sensitive noncompetitive nonisotopic assay of LR3IGF-I. Mouse IgG 1A7-F5-E5 binds an epitope that contains the substituted arginine3 in LR3IGF-I and was used as the solid phase antibody. The solution phase antibody was a rabbit immunoglobulin Nelson which binds to an epitope that is common to IGF-I and LR3IGF-I. The ELISA system was able to detect as little as 50 pg LR3IGF-I in 100 microliters and the native peptides IGFs-I and -II have less than 0.01% activity. Blood plasma from animals treated with pharmacologically active doses of this growth factor analog could be diluted 33.3-fold before assay, at which concentrations plasma had no significant effect on the assay. The ELISA response to LR3IGF-I was unaffected by the presence of IGF-binding proteins. The intra-assay and interassay coefficients of variation are 2.8 and 7.3% respectively. Recovery of LR3IGF-I added to blood plasma was approximately 90%. The ELISA was used to measure LR3IGF-I concentrations in plasma of cows treated with a pharmacologically active dose of this peptide and the results were compared with those obtained by a previously established LR3IGF-I RIA that requires size exclusion chromatography of plasma under acidic conditions to eliminate IGF-binding protein artefacts from the RIA. There was a positive correlation between results obtained by the two assays. The LR3IGF-I ELISA permits discrimination between the exogenous synthetic IGF-I analog and the endogenous native IGFs-I and -II in animals treated with this growth factor without the need for radioiodination of LR3IGF-I and elimination of the requirement for extraction of plasma before assay.